Search | Clinical Trials Finder

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 50
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 40 more

Conditions: Gastric Cancer
Interventions: Molecular testing for all participants., Germline Testing, Survey; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: GERD, Dysbiosis
Interventions: Not listed
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 2 Months to 12 Months
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Bladder Cancer
Interventions: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Traverse City, Michigan + 8 more

Conditions: Osteo Arthritis Knee
Interventions: Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Adult Subjects
Interventions: Complex oligosaccharide, Probiotic, PPI, H2 Blocker; Dietary Supplement · Other
Lead sponsor: Prolacta Bioscience; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Neoplasms, Malignant
Interventions: Cabazitaxel (XRP6258); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Decatur, Illinois + 5 more

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4; Other · Drug
Lead sponsor: Russell Richardson; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Cancer, Urothelial Carcinoma
Interventions: avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Neoplasms, Malignant
Interventions: cabazitaxel, gemcitabine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Clostridium Difficile Infection
Interventions: Omeprazole (suspension), Lifestyle Modification; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 0 Years to 4 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
Interventions: paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 14 Years and older · Male only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 77
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more

Conditions: Ovarian Neoplasms, Ovarian Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, Rescue Medications; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 26
States / cities: Birmingham, Alabama • Walnut Creek, California • Miami Beach, Florida + 22 more

Conditions: Non-Muscle Invasive Bladder Cancer
Interventions: Sacituzumab tirumotecan, Rescue medication, Supportive care measures; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 25
States / cities: Fort Myers, Florida • Miami Beach, Florida • West Palm Beach, Florida + 20 more

Conditions: Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions: Famotidine, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Minute to 12 Months
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more

Conditions: Mesothelioma
Interventions: LMB-100, ipilimumab, Diphenhydramine, Famotidine, Acetaminophen, Dexamethasone, Biopsy, FDG-PET, CT CAP, MRI, ECG, Echocardiogram; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Neoplasm Malignant
Interventions: MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Clermont, Florida • Chicago, Illinois • Portland, Oregon

Conditions: Laryngomalacia, Acid Reflux, Stridor
Interventions: ranitidine or famotidine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 4 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions: Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more

Search by objective public record fields.

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

How Reflux Medications Affect the Microbiome of Infants

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

Dietary Supplement With and Without a Probiotic

Effect of Cabazitaxel on the QTc Interval in Cancer Patients

: Vascular Function in Health and Disease

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Effect of Acid Suppression Medication on Pediatric Microbiome

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)